NCT04079140COMPLETEDanonymous

Benefits of Self-administered Vaginal Dinoprostone Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women: a Randomized Controlled Trial

Sponsor

Source record

Cairo University

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Dinoprostone, placebo

Indication / condition

AI-normalized

IUD Insertion Pain

Intervention

Source record

Dinoprostone, placebo

Related intelligence directories

Indication directory: IUD Insertion Pain Modality directory: small molecule Target directory: Dinoprostone

Source & freshness

Source record

NCT ID

NCT04079140

Original source

ClinicalTrials.gov

Source last updated

Jul 31, 2020

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04079140

Title

Benefits of Self-administered Vaginal Dinoprostone Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women: a Randomized Controlled Trial

Sponsor

Cairo University

Status

COMPLETED

Phase

PHASE4

Condition raw

IUD Insertion Pain

Condition normalized

IUD Insertion Pain

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dinoprostone, placebo

Target normalized

Dinoprostone, placebo

Interventions

Dinoprostone, placebo

Public preview

Source record

To investigate whether vaginal dinoprostone administered before the levonorgestrel-releasing intrauterine system(IUs) insertion reduces IUD insertion pain and difficulty in insertion in adolescents and young women.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Benefits of Self-administered Vaginal Dinoprostone Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women: a Randomized Controlled Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT04079140

Status

COMPLETED

Phase

PHASE4

Sponsor

Cairo University

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 31, 2020

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04079140

Indication

IUD Insertion Pain

Modality

small molecule

Target

Dinoprostone, placebo

Intervention

Dinoprostone, placebo

Source record